All News

Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.

A quick quiz covering new research on menopause hormone therapy, Alzheimer risk, tirzepatide weight loss, and estetrol’s cardiovascular safety.

The rate of AF recurrence was reduced significantly and participants also experienced improvements in self-reported AF severity as well as improved cardiometabolic measures.

Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.

TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.

Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.

TMS 2025: Jiang explains why he investigated hormone therapy's effect on autoimmune disease risk in postmenopausal women.

The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.

One in ten adults report NCGWS, frequently coexisting with IBS, anxiety, or depression, suggesting a central role for the gut-brain axis in pathophysiology.

New research from TMS 2025 covers menopause effects on brain volume, hormone therapy's role in weight loss with GLP-1s, and dense breast screening updates.

Catch up on the 7 FDA drug approvals from Q3 2025 most relevant to primary care, including new treatments for cardiometabolic, infectious, and inflammatory diseases.

Smoking drives lung cancer deaths, but race predicts breast/prostate mortality. New study reveals distinct community factors for each cancer type's outcomes.

Common questions on the critical window hypothesis for timing of postmenopausal MHT ask about rationale, clinical evidence, and guideline response.

Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.

Menopause specialist Caroline Mitchell, MD, MPH, explains the dual nature of the breakdown in communication that can leave women virtually uninformed about GSM and treatment.

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.